1Y Close · As of Aug 26, 2026
Medy-Tox operates in the Pharmaceuticals sector.
Legal name: Medy-Tox Inc.
In fiscal year 2025, Medy-Tox (086900) reported revenue of 247.3 billion KRW, up 8.2% from 228.6 billion KRW a year earlier.
Operating profit was 17.0 billion KRW and net income was 15.7 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 500.7 billion KRW, with a P/B of 1.10.
These figures can be verified in the DART filing (receipt no. 20260319001223).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2025 | 247.3B | 17.0B | 15.7B |
| 2024 | 228.6B | 20.3B | 16.1B |
| 2023 | 221.1B | 17.3B | 9.7B |
Recent Filings
Large Shareholding Report (General)
Semi-Annual Report (2026.06)
Consolidated Operating (Preliminary) Earnings (Fair Disclosure)
Checks
No items require attention at this time.
Market Cap & Price: Market cap is above the delisting threshold.
Administrative Designation: No administrative designation criteria met.
Audit Opinion: Audit opinion: Unqualified (clean).
Convertible Bonds: No convertible bonds outstanding.
Capital Increase: No capital-increase filings in the last 180 days.
Treasury Stock: Treasury stock filings in the last 3 years: 2 acquisition(s), 1 cancellation(s).
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Market Action: No market actions recorded in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-28 | Large Shareholding Report (General) |
| 2026-08-13 | Semi-Annual Report (2026.06) |
| 2026-08-10 | Consolidated Operating (Preliminary) Earnings (Fair Disclosure) |
| 2026-08-03 | Officer/Major Shareholder Ownership Report |
| 2026-07-30 | Officer/Major Shareholder Ownership Report |